Management of treatment-naïve diabetic macular edema patients: Review of real-world clinical data
- 11 March 2024
- journal article
- review article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 34 (6) , 1675-1694
Abstract
The high prevalence of Diabetic macular edema (DME) is a real global health problem. Its complex pathophysiology involves different pathways. Over the last decade, the introduction of intravitreal treatments has dramatically changed the management and prognosis of DME. Among the different treatment options, inhibitors of vascular endothelial growth factor (anti-VEGF) and intravitreal steroids implants represent the first-line therapy of DME. We conducted a review of electronic databases to compile the available evidence about the clinical management of DME in a clinical setting, with a special focus on treatment-naïve patients. Anti-VEGF therapies represent a valuable option for treating DME patients. However, many patients do not respond properly to this treatment and, due to its administration regimen, many patients receive suboptimal treatment in real life. Current evidence demonstrated that in patients with DME, DEX-i improved significantly both anatomic and visual outcomes. Besides eyes with insufficient anti-VEGF respond or recalcitrant DME cases, DEX-i can be effectively and safely used in treatment-naïve DME patients as first line therapy. DEX-i may be considered first line therapy in different clinical scenarios, such as DME eyes with a greater inflammatory component, patients with cardiovascular events, vitrectomized eyes, or those requiring cataract surgery. In conclusion, there are still many points for improvement pending in the clinical management of the patient with DME. Since DME treatment must follow a patient-tailored approach, selecting the best therapeutic approach for each patient requires a good understanding of the pathophysiology of DME.Keywords
Funding Information
- AbbVie SRL
This publication has 211 references indexed in Scilit:
- Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON studyGraefe's Archive for Clinical and Experimental Ophthalmology, 2020
- Ranibizumab und Aflibercept bei diabetischem Makulaödem – Retrospektive Studie mit Ergebnissen aus dem klinischen Alltag nach 12 MonatenDer Ophthalmologe, 2019
- Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edemaActa Diabetologica, 2018
- Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data QualityClinical Pharmacology & Therapeutics, 2017
- Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedemaGraefe's Archive for Clinical and Experimental Ophthalmology, 2016
- A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular EdemaArchives of Ophthalmology (1950), 2012
- An Integrated Approach to Diabetic Retinopathy ResearchArchives of Ophthalmology (1950), 2011
- Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES)Graefe's Archive for Clinical and Experimental Ophthalmology, 2007
- Vitreous Levels of Vascular Endothelial Growth Factor and Stromal-DerivedFactor 1 in Patients With Diabetic Retinopathy and Cystoid Macular Edema Beforeand After Intraocular Injection of TriamcinoloneArchives of Ophthalmology (1950), 2004
- Cataract surgery in patients with diabetic retinopathy: Visual outcome, progression of diabetic retinopathy, and incidence of diabetic macular oedemaGraefe's Archive for Clinical and Experimental Ophthalmology, 2002